A novel formulation enabled transformation of 3 HIV drugs tenofovir-lamivudine-dolutegravir (TLD) from short-acting to long-acting all-in-one injectable
Simone Perazzolo, Zachary Stephen, Masa Eguchi, Xiaolin Xu, Rachele Delle Fratte, Ann C. Collier, Ann J. Melvin, Rodney J.Y. Ho- Infectious Diseases
- Immunology
- Immunology and Allergy
Objective:
To develop an injectable dosage form of the daily oral HIV drugs, tenofovir (T), lamivudine (L), and dolutegravir (D), creating a single, complete, all-in-one TLD 3-drug-combination that demonstrates long-acting pharmacokinetics.
Design:
Using drug-combination-nanoparticle (DcNP) technology to stabilize multiple HIV drugs, the 3 HIV drugs TLD, with disparate physical-chemical properties, are stabilized and assembled with lipid-excipients to form
Results:
Following single-dose
Conclusions:
This study confirms that TLD with disparate properties can be made stable by DcNP to enable TLD concentrations of 4 weeks in NHP. Study results highlighted the potential of